Direct compression tablet manufacture for canine and feline acid suppression begins with famotidine veterinary grade API as a thiazole-containing histamine H2 receptor antagonist. The material is a white to pale yellowish-white crystalline powder with a molecular formula of C8H15N7O2S3 and a molecular weight of 337.45 g/mol. Tablet strengths of 10 mg, 20 mg, and 40 mg are compounded with direct compression excipients, typically microcrystalline cellulose, lactose monohydrate, crospovidone, and magnesium stearate. Because famotidine exhibits weak basic character and pH-dependent aqueous solubility, dissolution testing is performed in an acidic medium providing sink conditions; compendial Apparatus 2 agitation at 50 rpm in 900 mL of acidic medium is widely applied for batch release. Content uniformity is assessed by USP <905>, with an acceptance value limit of 15 for 10 units and a unit assay window of 90.0% to 110.0%. In the United States, famotidine is not approved by FDA-CVM as a veterinary product; use in dogs and cats falls under extra-label provisions of 21 CFR Part 530. Direct compression is preferred over aqueous wet granulation when the API particle size is sufficiently fine, because famotidine can undergo moisture-induced agglomeration during high-shear granulation, which may alter disintegration behavior.

Compression force on a rotary tablet press equipped with 10 mm round tooling typically sits between 8 kN and 15 kN. Tablet hardness is maintained at 5 kp to 8 kp to avoid capping while preserving disintegration below 15 minutes in water at 37 °C. Famotidine API has a cohesive, static-prone habit; without fumed silica addition at 0.25% to 0.5% w/w, powder flow through discharge hoppers can become erratic on production lines. Blend uniformity is checked after a 30-minute bin blender cycle at 15 rpm, with a target assay relative standard deviation of ≤ 2.0% before compression. Tablets are then film-coated with an aqueous hypromellose-based dispersion to reduce dusting and improve palatability in small animals. The main process conflict is that the API is sensitive to over-lubrication; magnesium stearate above 1.0% w/w can delay dissolution by hydrophobic film formation on particles.

What Limits Terminal Sterilization Feasibility in Famotidine Injection Solutions?

Injectable famotidine is prepared as an aqueous solution at 10 mg/mL for intravenous or subcutaneous administration in dogs and cats. The API is dissolved in water for injection with an acidulent or buffer component to maintain a pH range that keeps the molecule in protonated form; a shift above the inflection region reduces solubility and may produce visible precipitation. Osmolality is adjusted with sodium chloride to a target of 290 mOsmol/kg to 310 mOsmol/kg and verified by USP <785> freezing-point osmometry. The solution is passed through a 0.22 µm sterilizing-grade membrane filter under aseptic conditions when terminal steam sterilization is not supported by the degradation profile. Portions of the filtered solution are filled into Type I borosilicate glass vials and stoppered with chlorobutyl elastomer closures. On manufacturing lines, the primary failure mode is filter blockage during aseptic filling if the API is not fully dissolved before filtration; a 0.45 µm clarifying filter is often placed upstream to reduce bioburden and particulate load.

Terminal steam sterilization at 121 °C for 15 minutes may be evaluated, but published data for this specific configuration is limited; forced degradation studies should compare assay loss, unspecified degradation product growth, and pH shift against the acceptance criteria of the target market. Sterility assurance is verified by USP <71> membrane filtration, and bacterial endotoxin limits are calculated from the maximum planned bolus dose under USP <85>. Batch release includes particulate matter testing by light obscuration according to USP <788> for small-volume injections. The injection route requires tight control of elemental impurities; routine screening follows ICH Q3D risk assessment for parenteral products. Production-scale stability protocols include appearance, pH, assay, related substances, sterility, and subvisible particulate count. Because famotidine is a weak base, any increase in headspace oxygen or loss of acidulent can alter pH and reduce solubility during long-term storage.

Equine oral powder formulations are compounded for gastroprotective administration at a dose of 1.0 mg/kg to 2.0 mg/kg every 12 hours. In the horse, published data indicate low and variable oral bioavailability, with reported values below 15%; therefore the powder is often dispersed in a small volume of tap water and administered by oral syringe rather than as a top dress on feed. The API is commonly triturated with a 1:9 or 1:19 diluent system using lactose monohydrate or maltodextrin to produce a uniform admixture for hand-filled hard gelatin capsules or single-dose sachets. The end-use product is a terminal pharmaceutical preparation from a compounding pharmacy or a registered veterinary medicine, not a simple repack of API; this distinction drives batch records, beyond-use dating, and label instructions for extra-label use in jurisdictions where famotidine is not approved for horses. Where non-sterile veterinary compounding is governed by USP <795>, beyond-use dating and documentation requirements apply.

Process control for equine oral powders focuses on sieve cut and blend uniformity. The API is passed through a 180 µm or 250 µm mesh before geometric dilution; static adhesion to polyethylene weigh boats and stainless steel scoops is a recognized yield risk. Blend homogeneity is tested by sampling from 10 locations of a V-blender after 20 minutes at 25 rpm. If the relative standard deviation of high-performance liquid chromatography assay exceeds 5.0%, the blend is re-sieved and reblended. Hard gelatin capsule fill weight is targeted at 250 mg to 500 mg, with powder bed height in the capsule hopper held below the maximum mark to avoid segregation of fine famotidine particles from coarse diluent particles. Dissolution testing for capsules follows compendial tablet monograph principles, but a product-specific method must be validated because the equine oral powder is a compounded preparation rather than an approved dosage form.

Granulation Endpoint Moisture Below 2.5% Prevents Polymorph Conversion During Storage

Granules and oral preparations for multi-species dosing are manufactured by wet high-shear granulation or fluid-bed top-spray granulation. The dry powder premix consists of famotidine, microcrystalline cellulose, hydroxypropyl methylcellulose, and a low-substituted hydroxypropyl cellulose disintegrant. Purified water or an aqueous binder solution is added at a spray rate that maintains a wet mass moisture level of 8% to 12% during high-shear kneading. The wet mass is discharged through a 1.0 mm screen and dried in a fluid-bed dryer to a final moisture endpoint of 2.0% to 2.5%. Drying below this range may increase friability, while drying above this range can cause storage-induced clumping and a shift in dissolution behavior. The endpoint is confirmed by loss on drying with a halogen moisture analyzer, because surface moisture is the critical variable for storage stability.

Residual solvent and degradation product control follow VICH GL18 and VICH GL11 stability frameworks. If isopropyl alcohol is used as a granulation solvent, residual content is limited to 0.5% w/w for Class 3 solvents; batch records must include a validated drying cycle and a gas chromatographic limit test. Granule physical testing includes bulk density, tapped density, and compressibility index; a compressibility index greater than 25% indicates poor flow and requires additional glidant. The final granule is filled into sachets or composite containers under relative humidity below 40% to limit moisture uptake on exposed surfaces. Production-scale losses occur most frequently at the granulator discharge screen, where a sticky wet mass can smear and clog the opening if binder viscosity is too high; reducing impeller speed rather than increasing water content is the standard corrective action.

When Premix Homogeneity Must Be Confirmed Across a 1:1000 Dilution Step

Feed premix manufacture of famotidine for food-producing animals is not a recognized commercial route in major regulatory jurisdictions. There is no harmonised maximum residue limit for famotidine in edible tissues, and no approved withdrawal period exists under FDA-CVM or European Union regulations for production animals. Premix work is therefore restricted to non-food animals or to extemporaneous preparation under veterinary directive where local law permits. Any premix project must first confirm that the target species and production class are not entering the human food chain; published data for production-animal in-feed efficacy are too limited to support conventional feed mill distribution. In the United States, medicated feed production for approved animal drugs falls under 21 CFR Part 225; famotidine does not have an approved Type A medicated article listing.

If a 1:1000 dilution premix is prepared for a non-food animal or an approved investigational setting, the API is pre-blended with a feed-grade carrier such as ground limestone or dextrose monohydrate in a geometric dilution sequence. A first trituration of 1:9 is made in a low-shear drum mixer for 10 minutes; this intermediate is then diluted to 1:99 and finally to 1:999 in a horizontal ribbon mixer or double-cone blender. Sampling at 10 points after the final mix must show an assay relative standard deviation of ≤ 5.0% and a mean assay of 90% to 110% of label. Dust extraction and electrostatic adhesion to stainless steel surfaces are significant sources of yield loss and cross-batch carryover; washdown must be confirmed by swab assay because visual inspection does not detect low-residue contamination.

Oral solution dosage forms are prepared at target concentrations of 2 mg/mL to 10 mg/mL for dogs, cats, small exotic species, and neonatal foals where weight-based dose adjustment is needed. The aqueous vehicle is acidified with a citrate or phosphate buffer to maintain pH in the range of 4.0 to 5.5 because famotidine solubility decreases as pH approaches the neutral region. A preservative system, usually sodium benzoate at 0.1% w/v or potassium sorbate at 0.15% w/v, is included in multi-dose containers to control bacterial and fungal growth. A viscosity modifier such as hydroxyethyl cellulose at 0.3% to 0.5% w/v may be added to reduce settling and improve oral syringe withdrawal. The solution is filled into amber polyethylene terephthalate bottles with child-resistant closures and stored at 2 °C to 8 °C; beyond-use dating is determined by a stability protocol that includes assay, pH, preservative efficacy, and visual precipitation.

Manufacture of oral liquids must account for the pH-solubility curve of famotidine and the risk of pH drift during storage. If buffer capacity is insufficient, carbon dioxide absorption from headspace air can gradually raise pH and produce low-level precipitation on the bottle wall that is not detected by shake tests. Terminal filtration through a 10 µm or 20 µm screen is common before filling; a 0.22 µm sterilizing filter is used only for sterile oral syringes intended for immunocompromised neonates. Fill volume uniformity is checked according to USP <698> or equivalent national pharmacopoeial transfer volume tests. The most frequent production deviation observed on a multi-species oral liquid line is nozzle clogging caused by partially hydrated viscosity modifier; a high-shear dispersion step prior to final dilution minimizes this condition. Because famotidine is a weak base at the formulation pH, compatibility with rubber tip seals and oral syringe silicone lubricant should be evaluated by extraction and assay recovery over the intended in-use period.